web analytics

GenViro In Asia Boosts Decision Diagnostics Corp (OTCMKTS: DECN)

0

Decision Diagnostics Corp (OTCMKTS: DECN) is one again on the move up the charts and investors are paying attention as this one can move fast. The stock saw lows of $0.05 after the suspension but has come back to previous levels since. DECN has quickly attracted legions of shareholders who continue to bid the stock higher.

DECN is surging higher after the Company said it has entered into a written distribution agreement for its GenViro! Covid-19 10.5 Second Swift Kit and other products with Global Swift Sensor Distribution, who will represent the company’s GenViro! and GenUltimate products on a non-exclusive but first-to-market basis in India, Sri Lanka, Singapore, Malaysia, Indonesia, Thailand, Vietnam, Nepal, Bangladesh and Australia. The company also said it is evaluating two additional distribution offers from Brazil and Argentina (as a combined distributorship) as well as separate proposals for distributorships in Nigeria and the Philippines with the Nigeria distributorship closer to completion.

Decision Diagnostics Corp (OTCMKTS: DECN) started off as a nationwide prescription and non-prescription diagnostics and home testing products distributor. We market our GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), our panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), our GenPrecis test strips and meter (for private label sale), and our GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. We are also FDA approved and have complete R&D and manufacturing facilities in South Korea. We made the the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early 2008.

The Big Story on DECN is its GenViro(TM) Corona Virus Screening Kit which “provides results in 15 seconds, based on a small finger prick blood sample.” The company’s methodology employs a simple, easy to use, swift (15 seconds and faster than Rapid) method for determining the presence of a virus in blood lyced into blood plasma. Blood sample requirements are 1-2 microliters. DECN designed and tested the kit in Daegu, South Korea already and therefore are confident of the success of their kit application testing for the FDA.

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECN

On Wednesday DECN said it plans to manufacture two GenViro! International Covid-19 Swift Kit packages for sale in Central and Southern Asia and reports that its new distributor will be opening hubs in Singapore, India and Australia. The distributor has agreed to have these hubs managed locally by equity personnel selected specifically for their knowledge and experience in dealing with the national and local governments where the GenViro! Swift Kit will be available. The company still estimates that sales for its International GenViro! Swift Kits will commence in late Summer 2020. The new distributorship has agreed to buy the GenViro! and GenUltimate products in international packaging and their particular product requests are now being initiated by the company. As the company is announcing these distribution agreements and the opening of markets for global sales, it also announced it has filed for a Provisional Patent for its GenUltimate TBG product technology, in what it believes to be a significant milestone in the continued development of its proprietary technology.

“While we have remained in regular contact with the U.S. FDA and are looking toward an authorization for our GenViro! Covid-19 :10.5 Swift Kits to permit sales in the United States and Puerto Rico, the company has conducted and continues to conduct appropriate testing, and has been busy assembling the network of distributors and relationships internationally to bring our critically needed Covid-19 testing to these foreign markets. Finally, we are almost there,” said Keith Berman CEO of DECN. “We are seeing huge interest in the GenViro! Swift Kit from potential partners across the globe and are actively planning our manufacturing requirements to meet the expected demand. We anticipate a number of these countries to have the ability to conduct our Covid-19 virus antigen testing in a matter of weeks, and look forward to seeing such testing grow rapidly. In the midst of this flurry of international distribution activity, we are also conducting final interviews to select a clinical trial partner who will create a new testing protocol for for GenViro! testing using the FDA’s newly revised testing protocols. We do expect to come to agreement on testing.”

We have a Monster Pick Coming. Subscribe Right Now!

Currenly running up the charts DECN is one again on the move up the charts and investors are paying attention as this one can move fast. The stock saw lows of $0.05 after the suspension but has come back to previous levels since. DECN has quickly attracted legions of shareholders who continue to bid the stock higher. According to DECN its GenViro(TM) Corona Virus Screening Kit easily tops anything on the market; GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. On Wednesday DECN said it plans to manufacture two GenViro! International Covid-19 Swift Kit packages for sale in Central and Southern Asia and reports that its new distributor will be opening hubs in Singapore, India and Australia. Microcapdaily has been covering DECN since the stock was .o3. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.